Clinical practice and access to care at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
87 organizations at ASH 2026 present work in clinical practice & access to care: 32 hospitals and cancer centres, 26 universities and research institutes, 18 government and non-profit bodies, 10 suppliers and service providers and 1 pharma or biotech company. Between them they bring 88 presentations to the program. Most represented: Dana-Farber Cancer Institute (18 on the program), Mayo Clinic (11 on the program), Moffitt Cancer Center (10 on the program). 59 of them have their own page in this guide. As of Sep 27, 2026.
Format
Top represented
Showing 1–3 of 87 organizations
| Organization | ASH 2026 Attendance |
|---|---|
Dana-Farber Cancer Institute Boston, MA | |
Harvard-affiliated cancer treatment and research center in Boston, Massachusetts. | Symposium Fri Dec 11 11:00am–2:00pm Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum Bispecific antibodies in relapsed diffuse large B-cell and follicular lymphoma, from sequencing with CAR-T to outpatient step-up dosing and side effects. Symposium Fri Dec 11 11:00am–2:00pm Cases and Conversations™: Precision Care in BPDCN—Integrating Updated Diagnostic Pathways With Current and Emerging CD123-Directed Therapies Diagnosing blastic plasmacytoid dendritic cell neoplasm and treating it with drugs aimed at the interleukin-3 receptor, while managing capillary leak syndrome. Symposium Fri Dec 11 11:00am–2:00pm Decoding High-Risk AML: Applying Molecular Insights to Clinical Decision-Making Using tests for isocitrate dehydrogenase and Flt3 mutations to guide targeted therapy choices in acute myeloid leukemia. Symposium Fri Dec 11 3:00pm–6:00pm FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment Time-limited frontline chronic lymphocytic leukemia treatment pairing Bruton tyrosine kinase and Bcl-2 inhibitors, tailored to patient goals and risk. Symposium Fri Dec 11 7:00am–10:00am MDS in Practice: Navigating Complex Decisions Across the Disease Spectrum Managing myelodysplastic neoplasms across their spectrum, from clonal hematopoiesis and lower- and higher-risk disease to overlap syndromes and leukemia. Symposium Fri Dec 11 7:00pm–10:00pm Overcoming the Challenges of Managing Adolescents and Young Adults With Ph-Negative Acute Lymphoblastic Leukemia Pediatric-style regimens, asparaginase, immunotherapy, and CAR-T for teens and young adults with acute lymphoblastic leukemia, plus their psychosocial needs. Symposium Fri Dec 11 11:00am–2:00pm Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse. Symposium Fri Dec 11 11:00am–2:00pm The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care Cereblon-modulating protein degraders for relapsed myeloma, from biology and trial data to sequencing, neutropenia management, and residual disease testing. Session Single-Cell and Spatial Genomics Redefining the Immune Cell Landscape in AML/MDS Single-cell and spatial maps of bone marrow in acute myeloid leukemia and myelodysplastic neoplasms, showing how immune cell niches help tumors evade immunity. Session Back to the Future: Using Old and New Tools to Move the Field of Plasma Cell Research Forward Old and new tools, from biochemistry and mouse models to spatial gene mapping and AI, revealing weak points and treatment biomarkers in multiple myeloma. Talk Show Me Your Face and I Will Understand Your Purpose: How Protein Structure Informs Function Structural biology uncovered a second route for destroying the transcription factors multiple myeloma depends on, making that pathway a possible drug target. Talk From Frontier to Field: Manufacturing Innovations That Could Lower Barriers to CAR-T Access in LMICs Manufacturing advances from wealthy countries that could make CAR-T therapy cheaper and easier to deliver in low- and middle-income countries. Talk Targeting Acute and Chronic GVHD with Effective New Therapies Recently approved treatments for steroid-resistant acute and chronic graft-versus-host disease, including ruxolitinib, belumosudil, axatilimab and stromal cells. Talk Dealing with Workforce Challenges in Classical Hematology What drives the shortage of specialists in non-cancer blood disorders, and early results from efforts to close the gap. |
Mayo Clinic Rochester, MN | |
Non-profit academic medical center with main campuses in Minnesota, Arizona and Florida, providing patient care, research and education. | Symposium Fri Dec 11 11:00am–2:00pm Actionable Approaches to AL Amyloidosis Care: Diagnosing Earlier, Treating Smarter, Managing Together Diagnosing light-chain amyloidosis earlier, personalizing treatment including fibril-targeting drugs, supporting patients, and improving team workflows. Symposium Fri Dec 11 7:00am–10:00am Anti-BCMA Bispecific Antibodies in Multiple Myeloma: From Biology to Real-World Implementation Bispecific antibodies targeting B-cell maturation antigen in myeloma, from mechanism and resistance to trial data, outpatient dosing, and infection prevention. Symposium Fri Dec 11 11:00am–2:00pm Transforming Care for Newly-Diagnosed Multiple Myeloma: Integrating Evidence-Based Innovation into Community Practice Newly diagnosed multiple myeloma care in community clinics, using frailty assessment, dose adjustment to protect quality of life, and new drug formulations. Talk Running on Wheels: How Mouse Models Inform the Study of Plasma Cell Biology Immune-competent mouse models of multiple myeloma that mimic its interplay with bone marrow, used to test new immune and cell therapies before trials. Talk Clonal Dominance in VEXAS An adult-onset inflammatory blood disorder caused by mutation of one protein-tagging enzyme, and how extra mutations shape inflammation and treatment. Session Don't Miss It! Methemoglobinemia: Inherited and Acquired How to evaluate unexplained cyanosis, recognize inherited or acquired methemoglobinemia with lab tests, and manage it without costly unnecessary workups. Talk Laboratory Testing in Methemoglobinemia Lab diagnosis of methemoglobinemia and sulfhemoglobinemia, where altered hemoglobin carries oxygen poorly, and test pitfalls in inherited versus acquired cases. Talk Older Adults Take the Lead: Revolutionizing B-cell ALL Treatment with Chemo-Sparing Approaches Chemotherapy-light care of older adults with B-cell acute lymphoblastic leukemia, using fitness and residual disease to sequence immunotherapies and transplant. Talk Session Treating Fairly Rounds Lunch How hematologists and fellows can influence healthcare reform on research funding, Medicaid, and hospital budgets, and how policy shapes health inequities. |
Moffitt Cancer Center Tampa, FL | |
NCI-designated comprehensive cancer center in Tampa, Florida, working on cancer prevention, treatment, research and training. | Booth Exhibiting at Booth 3623 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 11:00am–2:00pm Advancing Bispecific Pathways in ALL: How Clinical Experience and New Science are Informing Off-the-Shelf Innovation Bispecific T-cell engagers in B-cell acute lymphoblastic leukemia, including gentler next-generation versions for patients unsuited to or relapsing after CAR-T. Symposium Fri Dec 11 11:00am–2:00pm CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation CAR-T for relapsed B-cell lymphomas, from patient selection and referral to managing immune and nerve toxicities, survivorship, and off-the-shelf products. Symposium Fri Dec 11 11:00am–2:00pm CML Treatment Continuum: Optimizing Therapy Selection, Molecular Monitoring, And Long-Term Quality of Life First-line drug choice, resistance, long-term side effects, and treatment-free remission in chronic myeloid leukemia, plus pipeline agents. Symposium Fri Dec 11 3:00pm–6:00pm MDS in the Modern Era: Getting Ahead of the 8-Ball Moving myelodysplastic syndrome care toward early disease-modifying drugs, with hypomethylating agents for higher-risk disease and wider transplant access. Symposium Fri Dec 11 3:00pm–6:00pm Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies. Symposium Fri Dec 11 3:00pm–6:00pm The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-Line to Frontline Care Bispecific antibodies moving from late to early treatment of non-Hodgkin lymphoma, with outpatient step-up dosing and control of immune side effects. Session Are We There Yet? Improving Outcomes in MDS Assessing and treating myelodysplastic syndromes, marrow failure cancers of older adults that can turn into acute myeloid leukemia, using newer risk systems. Session Medical Educators' Symposium Practical strategies for medical educators on time management, wellness, inclusive learning spaces, and teaching with AI, apps, and social media. |
Instantly find 20 buyers in clinical practice & access to care
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ASH 2026 by
Organization type
Topic
- Leukemias, MDS & MPN 110
- Lymphoma & CLL 81
- Myeloma & Amyloidosis 74
- Bispecifics, ADCs & Targeted Drugs 92
- Transplant, Cell & Gene Therapy 86
- Sickle Cell, Anemia & Red Cell Disorders 76
- Bleeding, Clotting & Platelets 53
- Stem Cells & Blood Biology 52
- AI, Genomics & Data 42
- Clinical Practice & Access to Care 87
Exhibit hall
Everyone
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction